Catalyst Pharmaceutical
CPRX
50 hedge funds and large institutions have $81.3M invested in Catalyst Pharmaceutical in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 12 closing their positions.
190% more call options, than puts
Call options by funds: $142K | Put options by funds: $49K
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
3% more capital invested
Capital invested by funds: $78.7M → $81.3M (+$2.61M)
4% less funds holding
Funds holding: 52 → 50 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.6M |
| 2 |
BC
Broadfin Capital
New York
|
+$2.74M |
| 3 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$2.27M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.03M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$686K |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.43M |
| 2 |
VAM
Visium Asset Management
New York
|
-$2.08M |
| 3 |
Morgan Stanley
New York
|
-$1.58M |
| 4 |
Renaissance Technologies
New York
|
-$652K |
| 5 |
Millennium Management
New York
|
-$275K |
CPRX Hedge Fund Activity: Q4 2014 in Review
50 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2014, worth a combined $81.3M — up 3.3% from $78.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CPRX and 10 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 16 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.6M. The largest seller was Federated Hermes, cutting an estimated $4.43M.
- 50 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2014, down from 52 in Q3 2014.
- Funds reported $81.3M of Catalyst Pharmaceutical stock for Q4 2014, up 3.3% quarter-over-quarter.
- 10 funds opened new Catalyst Pharmaceutical positions in Q4 2014 and 12 closed out, a net change of -2 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2014 was Point72 Asset Management, an estimated $9.6M added.
- The largest Catalyst Pharmaceutical seller in Q4 2014 was Federated Hermes, an estimated $4.43M sold.
Based on aggregated 13F filings for Q4 2014.